A novel in vivo mouse model applicable for SARS-CoV-2 infection study was established by using immunodeficiency mice subcutaneously implanted with human lung tissues. The implanted lung tissues effectively support viral replication as well as cause COVID-19-like immune- and histopathological phenotypes by an direct injection of SARS-CoV-2 into the tissues. Using this model, not only SARS-CoV-2 but also endogenous SARS-like bat coronaviruses were shown to be capable to infect to human respiratory tissues. This model was also valuable to test the efficacy of antiviral agents for SARS-CoV-2 infection, and it was demonstrated the therapeutic and prophylactic potential of an oral broad spectrum ribonucleoside analogue, EIDD-2801 for COVID-19.
No comments:
Post a Comment